Actively Recruiting
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Led by Fudan University · Updated on 2025-07-10
2000
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.
CONDITIONS
Official Title
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age at least 18 years.
- Pathologically confirmed diagnosis of a solid tumor cancer.
- Patients receiving treatment with immune checkpoint inhibitors.
- Ability to understand and willingness to provide the informed consent.
You will not qualify if you...
- Age less than 18 years.
- Patients with hematological malignancies or solid benign tumors.
- Mental disorders, drug abuse, or social conditions that may negatively impact compliance in the opinion of the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
Research Team
Z
Zhengfei Zhu, MD
CONTACT
J
Jianjiao Ni, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here